- Home
- ALAR vs GNTA Comparison
ALAR vs GNTA Comparison
Compare ALAR & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- GNTA
- Stock Information
- Founded
- ALAR 2013
- GNTA 2014
- Country
- ALAR Israel
- GNTA Italy
- Employees
- ALAR N/A
- GNTA N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALAR Technology
- GNTA Health Care
- Exchange
- ALAR Nasdaq
- GNTA Nasdaq
- Market Cap
- ALAR 71.4M
- GNTA 67.4M
- IPO Year
- ALAR 2018
- GNTA 2021
- Fundamental
- Price
- ALAR $10.38
- GNTA $4.40
- Analyst Decision
- ALAR Strong Buy
- GNTA Strong Buy
- Analyst Count
- ALAR 2
- GNTA 1
- Target Price
- ALAR $25.50
- GNTA $25.00
- AVG Volume (30 Days)
- ALAR 208.3K
- GNTA 8.2K
- Earning Date
- ALAR 11-26-2024
- GNTA 01-01-0001
- Dividend Yield
- ALAR N/A
- GNTA N/A
- EPS Growth
- ALAR N/A
- GNTA N/A
- EPS
- ALAR 0.07
- GNTA N/A
- Revenue
- ALAR $31,117,000.00
- GNTA N/A
- Revenue This Year
- ALAR $22.15
- GNTA N/A
- Revenue Next Year
- ALAR $11.59
- GNTA N/A
- P/E Ratio
- ALAR $18.07
- GNTA N/A
- Revenue Growth
- ALAR 52.26
- GNTA N/A
- 52 Week Low
- ALAR $2.92
- GNTA $2.20
- 52 Week High
- ALAR $46.69
- GNTA $5.87
- Technical
- Relative Strength Index (RSI)
- ALAR 36.20
- GNTA 59.13
- Support Level
- ALAR $9.76
- GNTA $3.86
- Resistance Level
- ALAR $12.80
- GNTA $4.50
- Average True Range (ATR)
- ALAR 0.83
- GNTA 0.31
- MACD
- ALAR 0.35
- GNTA 0.09
- Stochastic Oscillator
- ALAR 20.39
- GNTA 100.00
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.